Exposure to Infliximab During Pregnancy: Post-Marketing Experience
نویسندگان
چکیده
منابع مشابه
Exposure to sibutramine during pregnancy.
QUESTION One of my patients who was taking sibutramine to lose weight found out that she had unexpectedly conceived. The medication was stopped as soon as she found out, about 5 weeks into the pregnancy. Is the baby at risk? Should the pregnancy be aborted? ANSWER No data to date suggest that involuntary exposure to sibutramine during pregnancy carries major risk of congenital malformations. ...
متن کاملExposure to electromagnetic fields during pregnancy.
QUESTION Several of my patients quote recent media coverage claiming that working with home appliances could increase the risk of misarriages. What is your advice? ANSWER Two recent epidemiologic studies from California have suggested an increased risk of miscarriages associated with exposure to magnetic fields. Even if the threshold associated with such risk is a biologic and true risk (and ...
متن کاملRelationship between the Exposure to Magnetic Fields during Pregnancy and Risk of Abortion: A Review Article
Background Exposure to electro-magnetic fields is a risk factor for abortion. We aimed to review the relationship between exposure to magnetic fields during pregnancy and the risk of abortion. Materials and Methods: Two independent researchers screened the articles with related keywords including: "Radiofrequency", "RF", "RF-EMFs",...
متن کاملexposure to second-hand smoke during pregnancy and preterm delivery
background prematurity is an issue related to increasing the neonatal morbidity and mortality and smoking pregnant women cause the risk of low birth weight and prematurity increase, compared to non-smoking ones. results of all 205 women, 43 (20.97%) women exposed to shs during pregnancy and 162 (79.02%) women did not. in shs exposure group, 11 infant (25.6%) and in non- shs exposure group, 17 i...
متن کاملWeight and consequences of post-marketing (-approval) experience.
In the European Union the term pharmacovigilance is normally used to describe post-marketing or, more precisely, post-approval experience after the regulatory approval of drugs and their introduction to the market under defined conditions. The term describes activities used to gather information on the effects of medicinal products, with emphasis on those aspects which have not, or could not ha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Safety
سال: 2019
ISSN: 0114-5916,1179-1942
DOI: 10.1007/s40264-019-00881-8